Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2020)
Amarin Corp Plcuk (AMRN) reported Capital Expenditures of $1000.0 for Q3 2020, down 99.92% year-over-year from $1.3 million in Q4 2019, and down 99.6% quarter-over-quarter from $251000.0 in Q1 2020.
Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2020) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 10 years of Capital Expenditures data on file, last reported at $1000.0 in Q3 2020.
- Capital Expenditures for Q3 2020 came in at $1000.0, down 99.92% year-over-year; the trailing twelve-month figure through Dec 2020 was $252000.0 (down 85.02% YoY), and the FY2020 annual result was $252000.0, down 89.83% from the prior year.
- Capital Expenditures declined to $1000.0 in Q3 2020 per AMRN's latest filing, from $251000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.3 million in Q3 2019 and troughed at $1000.0 in Q3 2020.
- A 5-year average of $281000.0 and a median of $21000.0 in 2016 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2019 and 2020: Capital Expenditures soared 7180.0% in 2019, then plunged 99.92% in 2020.
- A 5-year view of Capital Expenditures shows it stood at $21000.0 in 2016, then tumbled by 42.86% to $12000.0 in 2017, then slumped by 58.33% to $5000.0 in 2018, then soared by 7180.0% to $364000.0 in 2019, then tumbled by 99.73% to $1000.0 in 2020.
- Business Quant data shows AMRN's Capital Expenditures at $1000.0 in Q3 2020, $251000.0 in Q1 2020, and $364000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -297.95 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 2.33 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 265.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 991.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 712.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 117.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 436.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 347.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Mar 31, 2020 | 251,000.00 |
| Mar 31, 2020 | 251,000.00 |
| Dec 31, 2019 | 364,000.00 |
| Dec 31, 2019 | 364,000.00 |
| Sep 30, 2019 | 1.31 Mn |
| Sep 30, 2019 | 1.31 Mn |
| Dec 31, 2018 | 5,000.00 |
| Dec 31, 2018 | 5,000.00 |
| Mar 31, 2017 | 12,000.00 |
| Mar 31, 2017 | 12,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Dec 31, 2015 | 18,000.00 |
| Dec 31, 2015 | 18,000.00 |
| Mar 31, 2013 | 14,000.00 |
| Mar 31, 2013 | 14,000.00 |
| Dec 31, 2012 | 72,000.00 |
| Dec 31, 2012 | 72,000.00 |